← Leaderboards
Laurel A. Lagenaur
Osel, Inc.
$6,537,797
Attributed
$6,537,797
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,537,797 · 8
By mechanism
R44$4,187,731 · 2
R33$1,135,690 · 1
R43$1,019,254 · 4
R21$195,122 · 1
Top collaborators
No co-investigators on record.
Most similar at Osel, Inc.
Same institution · by research overlap
- Qiang Xu$2,686,315
- Chia-Hwa Chang$245,089
- Thomas P Parks$678,082
Others in their field
Top investigators on “Lactobacillus”
- David Neal Fredricks · Fred Hutchinson Cancer Research Center$13,101,867
- Rebecca M. Brotman · University Of Maryland Baltimore$10,821,048
- Scott T Weiss · University Of California, San Diego$8,151,160
- Augusto A Litonjua · Brigham And Women'S Hospital$8,151,160
- Dorota Teresa Kopycka-Kedzierawski · University Of Rochester$7,709,608
- Moshe Arditi · Cedars-Sinai Medical Center$7,501,749
Research focus
LactobacillusWomanVaginaVaginal LactobacilliTransmission ProcessInfectionPreventHiv-1FemaleSimian Human Immunodeficiency VirusMacaca MulattaProteinsPathogenRecombinantsMicrobicideLifePre-ClinicalPreclinical SafetyBiomedical EngineeringBaseCyanovirin-NHiv Entry InhibitorsSafetyCervical
Grant awards (12)
Novel Antimicrobial Approach to Treat Chemoradiation Resistant Cervical Cancer by Selectively Inhibiting Lactobacillus iners$295,881
R43 · FY2025 · CA · contact PI
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial$463,683
R44 · FY2021 · AI · contact PI
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial$1,000,000
R44 · FY2020 · AI · contact PI
Development of a rapid point of care diagnostic,to monitor MucoCept-CVN, an HIV-targeted biotherapy,$225,000
R43 · FY2016 · AI · contact PI
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bioengineered to secrete broadly neutralizing domain antibodies$1,388,546
R44 · FY2015 · AI · contact PI
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bioengineered to secrete broadly neutralizing domain antibodies$1,335,502
R44 · FY2014 · AI · contact PI
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bi$299,870
R43 · FY2012 · AI · contact PI
Development of a Live Topical Microbicide for Women$364,466
R33 · FY2011 · AI · contact PI
Development of a Live Topical Microbicide for Women$425,654
R33 · FY2010 · AI · contact PI
Development of a Live Topical Microbicide for Women$345,570
R33 · FY2010 · AI · contact PI
Development of Bacterial Therapeutics Targeting Bacterial Vaginosis-Associated Bi$198,503
R43 · FY2010 · AI · contact PI
Development of a Live Combinational Microbicide for Women$195,122
R21 · FY2010 · AI · contact PI